Full Press Release Details
OLIVER SARTOR APPOINTED TO RADIOPHARM SCIENTIFIC
Sydney, Australia - 22 July 2025 - Radiopharm Theranostics
(ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative
oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce the appointment of Dr Oliver Sartor,
MD to the Company's Scientific Advisory Board (SAB).
Dr Sartor is an internationally recognised medical oncologist
and scientist specialising in prostate cancer and radiopharmaceutical therapies. He currently serves as Director of Radiopharmaceutical
Clinical Trials and Chair of the Genitourinary Cancer Disease Group at the world-renowned Mayo Clinic, in Rochester, Minnesota. He was
previously Laborde Professor of Medicine and Urology and Medical Director of Tulane Cancer Center in New Orleans under Tulane University
Dr Sartor has also held senior roles at LSU Health Sciences Center,
Dana-Farber/Harvard Medical School, and as Medical Oncology Co-Chair
of the GU Committee of NRG Oncology.
Dr Sartor received his MD with honours from Tulane University
School of Medicine in 1982, completed internal medicine residency at Tulane, and a medical oncology fellowship at the National Cancer
Since 1990 he has focused on prostate cancer clinical research, authoring
more than 500 peer-reviewed publications and leading multiple pivotal
Phase 3 trials that resulted in FDA approvals for therapies including samarium-153
EDTMP, cabazitaxel, radium-223, and PSMA-targeted
radioligand therapy.
"Dr Sartor brings an unparalleled depth of expertise in both
clinical translation and radiopharmaceutical therapies," said Riccardo Canevari, Managing Director and CEO of Radiopharm Theranostics.
"We're very honoured to welcome him to our SAB. His insight and leadership will be invaluable as we advance our radiopharmaceutical
About Radiopharm Theranostics
Radiopharm Theranostics is a clinical stage radiotherapeutics company
developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high
unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated
platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one
Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain metastases. Learn more at radiopharmtheranostics.com.
Authorized on behalf of the Radiopharm Theranostics Board of Directors
by Executive Chairman Paul Hopper.
Radiopharm Theranostics
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
For more information:
CEO & Managing Director
Follow Radiopharm Theranostics:
Website - https://radiopharmtheranostics.com/
Twitter - https://twitter.com/TeamRadiopharm
InvestorHub - https://investorhub.radiopharmtheranostics.com/
Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia